EDAP TMS SA to Announce First Quarter 2022 Financial Results on May 17, 2022

Rhea-AI Summary

EDAP TMS SA (Nasdaq: EDAP) will announce its Q1 2022 financial results on May 17, 2022, after market close. A conference call will take place on May 18, 2022, at 8:30 am EDT, featuring key executives including Marc Oczachowski and Ryan Rhodes. This event will provide insights into the company's performance in the therapeutic ultrasound market, where it leads in minimally invasive medical devices for prostate treatment.

More information and registration details are available through the webcast link.

Company to host conference call and webcast on, Wednesday, May 18^th at 8:30 am EDT

LYON, France, May 10, 2022 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31^st, 2022 after the markets close on Tuesday, May 17^th, 2022.

An accompanying conference call and webcast will be hosted by Marc Oczachowski, Chairman of the Board and Chief Executive Officer, Ryan Rhodes, CEO of EDAP U.S., and François Dietsch, Chief Financial Officer. The call will be held at 8:30am EDT on Wednesday, May 18^th, 2022. Please refer to the information below for conference call dial-in information and webcast registration.

Conference Call & Webcast
Wednesday, May 18^th @ 8:30am Eastern Time
Domestic:        877-451-6152
International:   201-389-0879
Passcode:        13728747
Webcast:        https://viavid.webcasts.com/starthere.jsp?ei=1541898&tp_key=e83b07e195

About EDAP TMS SA

A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit focalone.com, http://www.edap-tms.com, and us.hifu-prostate.com.

Company contact:
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com

Investor Contact
John Fraunces
LifeSci Advisors, LLC
212-915-2568
jfraunces@lifesciadvisors.com

 

FAQ

When will EDAP TMS release its first quarter 2022 financial results?

EDAP TMS will release its first quarter 2022 financial results on May 17, 2022, after market close.

What time is the EDAP TMS conference call scheduled?

The conference call for EDAP TMS is scheduled for May 18, 2022, at 8:30 am EDT.

Who will host the EDAP TMS conference call?

The conference call will be hosted by Marc Oczachowski, Ryan Rhodes, and François Dietsch.

How can I access the EDAP TMS conference call and webcast?

You can access the EDAP TMS conference call by dialing 877-451-6152 for domestic calls or 201-389-0879 for international calls, and using the passcode 13728747. The webcast link is also provided in the press release.

What is the focus of EDAP TMS in the medical devices market?

EDAP TMS focuses on developing and distributing minimally invasive medical devices using ultrasound technology, particularly in prostate cancer treatment.